Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease
Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab
1 other identifier
observational
119
1 country
1
Brief Summary
This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 9, 2024
CompletedFirst Posted
Study publicly available on registry
December 18, 2024
CompletedStudy Start
First participant enrolled
December 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2025
CompletedDecember 18, 2024
December 1, 2024
11 days
December 9, 2024
December 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
imaging remission rate of anal fistula
Treatment week 0 to 32
Eligibility Criteria
patients with perianal fistulizing Crohn's disease
You may qualify if:
- Clinical diagnosis of Perianal Fistulizing Crohn's Disease
- Receive ustekinumab therapy
You may not qualify if:
- Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs
- Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.
- Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.
- Combined with malignant tumor
- Clinical data missing ≥30% or no follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 9, 2024
First Posted
December 18, 2024
Study Start
December 20, 2024
Primary Completion
December 31, 2024
Study Completion
January 31, 2025
Last Updated
December 18, 2024
Record last verified: 2024-12